ReviewPathologie (Heidelberg, Germany)2025
[Hepatitis diagnostics : Differential diagnosis of viral hepatitis from other causes of elevated transaminases].
Review in Pathologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver biopsies in unclear hepatitis are required to assess etiology together with the clinico-serological findings to differentiate comorbidities. In addition, inflammatory activity should be graded, extent of necrosis estimated, and the stage of fibrosis determined in order to estimate pre-existing parenchymal damage. In liver biopsies from patients with acute liver failure, drug-induced liver injury, most often in idiosyncrasy is most common. While a liver biopsy is required for the diagnosis of autoimmune hepatitis, the diagnosis of viral hepatitis A-D is usually made clinically and serologically. Yet, hepatitis E is often underestimated: in addition to acute hepatitis in immunocompetent patients, hepatitis E-virus (HEV) infection may also manifest with a fulminant course in patients with pre-existing liver cirrhosis and follow a chronic course in immunocompromised patients.
Indexed as
Identifiers
40965633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.